Dx Revision Watch
Senior Member (Voting Rights)
My preference would be to refine the acronym ME, if needed, in the same way fibrositis became FM.
I've sometimes wondered if myasthenic encaphalopathy (brain dysfunction characterised by muscle weakness) would be better. It still retains the ME acronym without sceptics being able to leap on it as inaccurate.
On a side note: would it be worth implementing a 'no debates about criteria outside of threads explicitly on criteria' rule? It would stop the potential derails.
I feel I should mention that Fibromyalgia has lost its discrete code for ICD-11. For ICD-11, Fibromyalgia was relocated in May 2015 under the new Chronic primary pain block in the Symptoms, signs chapter. Rather than being assigned a new code in its new location, it is now rolled up an inclusion term under MG30.01 Chronic widespread pain in the ICD-11 equivalent of the Tabular List (which is the Mortality and Morbidity Statistics Linearization where the codes are) and takes the MG30.01 Chronic widespread pain code.
With regard to terminology and classification of the G93.3 legacy terms, this is an official WHO statement:
In response to the many proposals on Chronic fatigue syndrome, the WHO Secretariat has conducted a vast amount of research.
Findings: The condition is characterized by chronic, profound, disabling, and unexplained fatigue and coinciding symptoms such as sleep problems or post-exertional malaise. There is no agreement on a reliable diagnostic symptom pattern. The etiology is still being discussed and there is no uniform treatment approach with reliable outcomes. The only constant is the lead symptom ‘fatigue’ that persists over time.
Decision: As a result of this study, the category ‘postviral fatigue’ that is the indexing target, will not be changed as currently there is no evidence to suggest a better place. The entity will retain its name and remain within the Nervous system chapter.
The Medical and Scientific Advisory Committee and the Classification and Statistics Advisory committee supported this decision.
Team3 WHO 2018-Nov-19 - 07:10 UTC
Findings: The condition is characterized by chronic, profound, disabling, and unexplained fatigue and coinciding symptoms such as sleep problems or post-exertional malaise. There is no agreement on a reliable diagnostic symptom pattern. The etiology is still being discussed and there is no uniform treatment approach with reliable outcomes. The only constant is the lead symptom ‘fatigue’ that persists over time.
Decision: As a result of this study, the category ‘postviral fatigue’ that is the indexing target, will not be changed as currently there is no evidence to suggest a better place. The entity will retain its name and remain within the Nervous system chapter.
The Medical and Scientific Advisory Committee and the Classification and Statistics Advisory committee supported this decision.
Team3 WHO 2018-Nov-19 - 07:10 UTC
So until the science is there, good luck with any proposals for potential changes of terminology for "ME".
If the now sunsetted external Topic Advisory Group for Neurology and its internal Managing Editor/lead WHO Secretariat (Dr Tarun Dua) had had their way, CFS would have replace PVFS as the Title Concept (lead term); BME would have been the specified Inclusion term under CFS; and PVFS would have become an Index term. This is how the Beta draft had stood in early 2013.
And Dr Dua had wanted the terms deleted from the Neurology chapter and relocated under the Symptoms, signs chapter a child category under Symptoms, signs or clinical findings of the musculoskeletal system.
Last edited: